Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Pancreatic Cancer umbrella trial in metastatic pancreatic ductal adenocarcinoma
jRCT2031200298Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, tiragolumab, tocilizumab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Mar 2021; status: completed.
02
Drugs
atezolizumabtiragolumabtocilizumabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031200298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200298.